Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates

Corcept Therapeutics Incorporated (CORT) reported second-quarter 2024 earnings of 32 cents per share, which beat the Zacks Consensus Estimate of 23 cents. The company had reported earnings of 25 cents per share in the year-ago quarter. Quarter in Detail Research and development expenses surged 35.5% year over year to $58.7 million. Consequently, operating expenses increased to$128.2 million, up 45.5% from the year-ago quarter's level, owing to higher expenses related to ongoing clinical studies and support ...